Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marchetti, P.
Right arrow Articles by Del Prato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marchetti, P.
Right arrow Articles by Del Prato, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 51:1419-1424, 2002
© 2002 by the American Diabetes Association, Inc.

Brief Genetics Reports

Insulin Secretory Function Is Impaired in Isolated Human Islets Carrying the Gly972->Arg IRS-1 Polymorphism

Piero Marchetti1, Roberto Lupi1, Massimo Federici2, Lorella Marselli1, Matilde Masini4, Ugo Boggi4, Silvia Del Guerra1, Giovanni Patanè1, Salvatore Piro3, Marcello Anello3, Ettore Bergamini4, Francesco Purrello3, Renato Lauro2, Franco Mosca4, Giorgio Sesti5, and Stefano Del Prato1

1 Department of Endocrinology and Metabolism, Metabolic Unit, University of Pisa, Pisa, Italy
2 Department of Internal Medicine, University of Rome "Tor Vergata," Rome, Italy
3 Department of Endocrinology, University of Catania, Catania, Italy
4 Department of General Pathology, University of Pisa, Pisa, Italy
5 Department of Clinical and Experimental Medicine, University of Catanzaro "Magna Graecia," Catanzaro, Italy


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 
Type 2 (non–insulin-dependent) diabetes results from decreased insulin action in peripheral target tissues (insulin resistance) and impaired pancreatic ß-cell function. These defects reflect both genetic components and environmental risk factors. Recently, the common Gly972->Arg amino acid polymorphism of insulin receptor substrate 1 (Arg972 IRS-1) has been associated with human type 2 diabetes. In this study, we report on some functional and morphological properties of isolated human islets carrying the Arg972 IRS-1 polymorphism. Insulin content was lower in variant than control islets (94 ± 47 vs. 133 ± 56 µU/islet; P < 0.05). Stepwise glucose increase (1.7 to 16.7 mmol/l) significantly potentiated insulin secretion from control islets, but not Arg972 IRS-1 islets, with the latter also showing a relatively lower response to glyburide and a significantly higher response to arginine. Proinsulin release mirrored insulin secretion, and the insulin-to-proinsulin ratio in response to arginine was significantly lower from Arg972 IRS-1 islets than from control islets. Glucose utilization and oxidation did not differ in variant and wild-type islets at both low and high glucose levels. Electron microscopy showed that Arg972 IRS-1 ß-cells had a severalfold greater number of immature secretory granules and a lower number of mature granules than control ß-cells. In conclusion, Arg972 IRS-1 islets have reduced insulin content, impaired insulin secretion, and a lower amount of mature secretory granules. These alterations may account for the increased predisposition to type 2 diabetes in individuals carrying the Gly972->Arg amino acid polymorphism of IRS-1.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 REFERENCES
 
Type 2 (non-insulin-dependent) diabetes is the most frequent form of diabetes, and it affects ~5% of the population in Western countries (1). The association between type 2 diabetes and micro- and macrovascular complications, such as premature atherosclerosis, nephropathy, retinopathy, and neuropathy, has vast public implications. Consequently, intensive investigation into the causes of the disease to prevent its onset and optimize treatment after its diagnosis is required. Insulin resistance and impaired pancreatic ß-cell function are pathogenetic hallmarks of type 2 diabetes (2–4). Insulin resistance is often believed to precede the development of glucose intolerance and in the early stages is associated with enhanced ß-cell function that attempts to compensate for the reduced insulin sensitivity. As soon as insulin secretion becomes insufficient to meet the enhanced demand, diagnostic hyperglycemia develops. The progressive loss of insulin secretion is affected by a metabolic milieu (gluco- and lipotoxicity) acting upon a predisposing background. The predisposing condition is likely to result from the polygenic interactions of several simultaneously inherited gene mutations. To date, although some rare subtypes of type 2 diabetes have been described that are caused by mutations in genes encoding for crucial molecules involved in ß-cell development and function (i.e., glucokinase, hepatocyte nuclear factor 1 and 4, insulin promoter factor 1, insulin, and mitochondrial DNA) (4), the genetic basis of the common forms of type 2 diabetes has not yet been identified.

Almost a decade ago, Almind et al. (5) reported an association between the insulin receptor substrate 1 (IRS-1) polymorphism causing a Gly-to-Arg substitution at codon 972 (Arg972 IRS-1) and type 2 diabetes. IRS-1 is a major substrate for the insulin receptor and is present in tissues that are involved in glucose production, glucose clearance, and insulin secretion (6,7). It acts as a multisite docking protein that binds signal proteins and links the receptor kinase to a number of cellular functions that are regulated by insulin. For these reasons, the IRS-1 gene has been considered a candidate gene for common forms of type 2 diabetes. Indeed, after the above-mentioned study (5), several investigations have been performed, usually suggesting that the Arg972 IRS-1 polymorphism could predispose individuals to type 2 diabetes (8–12). A greater degree of insulin resistance in type 2 diabetic patients carrying the Arg972 IRS-1 polymorphism has been observed in some (13,14), but not all, investigations (15,16). Interestingly, type 2 diabetic patients as well as their nondiabetic nonobese first-degree relatives carrying the Arg972 IRS-1 polymorphism have lower fasting plasma insulin levels and lower insulin responses to glucose than noncarriers (17,18). Lately, it has been reported that normal glucose-tolerant subjects with the polymorphism have decreased insulin secretion and normal insulin sensitivity (19), thus suggesting that the Arg972 IRS modification can indeed play a role in ß-cell dysfunction.

Defects of insulin signaling at the ß-cell level have been shown to contribute to impaired insulin secretion (20–22). An impairment of glucose-mediated insulin secretion has been reported with disruption of the insulin receptor gene of the ß-cell (21), a knockout for islet IRS-1 (22), and overexpression of the Arg972 IRS-1 polymorphism in a rat insulinoma cell line (22). More recently, we have demonstrated that the Arg972 IRS-1 polymorphism impairs human pancreatic ß-cell survival and causes resistance to the anti-apoptotic effects of insulin (23).

Our laboratory processes pancreata of large mammals and humans on a regular basis for the preparation of isolated islets (24–27). We received pancreata from two nondiabetic donors (Table 1) in whom the Arg972 IRS-1 polymorphism was demonstrated; this gave us the unique opportunity to study a number of morphological and functional properties of the isolated islets and to compare the results with those obtained with the islets from two control donors (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1 Clinical characteristics of pancreas donors

 
When islet insulin content was measured, it was significantly lower in islets carrying the Arg972 IRS-1 polymorphism (94 ± 47 µU/islet; n = 33) than in wild-type islets (133 ± 56 µU/islet; n = 35; P < 0.05). Insulin mRNA levels analyzed by semiquantitative RT-PCR were slightly, but not significantly, decreased (by 13%) in variant islets compared with wild-type islets (data not shown). Insulin secretion results (expressed as percent of insulin content) in response to glucose, arginine, and glibenclamide are reported in Table 2. Control islets showed a progressive and significant potentiation of insulin release at increasing glucose concentrations (P < 0.05 by ANOVA). Conversely, the Arg972 IRS-1 islets had lower insulin secretion, with no significant increase in response to the stepwise increase of glucose levels in the medium. The Arg972 IRS-1 islets also showed a relatively lower insulin release in response to glibenclamide and a higher secretion of the hormone in response to arginine than control islets (Table 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2 Insulin release from control and Gly972 ->Arg IRS-1 islets in response to different stimuli

 
Table 3 illustrates proinsulin secretion. Similar to insulin release, proinsulin secretion from Arg972 IRS-1 islets showed no significant increase in response to glucose. When the insulin-to-proinsulin molar ratio was calculated, no significant difference was found between wild-type and polymorphic islets when the cells were challenged with glucose or glibenclamide (data not shown). However, a lower ratio was apparent for Arg972 IRS-1 than for control islets in response to arginine (4.4 ± 2.1 vs. 7.9 ± 2.9; P < 0.05).


View this table:
[in this window]
[in a new window]
  		TABLE 3 Proinsulin secretion results from control and Gly972->Arg islets in response to different stimuli

 
Glucose utilization and oxidation increased as a function of the increasing glucose concentration, both in control and Arg972 IRS-1 islets, with no difference between wild-type and variant islets (Table 4).


View this table:
[in this window]
[in a new window]
  		TABLE 4 Glucose utilization and oxidation in islets isolated from subjects carrying the Gly972->Arg IRS-1 polymorphism and in control islets

 
By electron microscopy, it was shown that the percent of ß-cells was similar in control islets (61 ± 3%) as in Arg972 IRS-1 islets (63 ± 2%). In addition, the amount of {alpha}-cells did not differ significantly between wild-type (22 ± 4%) and variant (16 ± 3%) islets. Quantification of ß-cell secretory granules indicated a greater number of immature and a severalfold lower amount of mature secretory granules in the Arg972 IRS-1 islets compared to control islets (Fig. 1 and Table 5).



View larger version (164K):
[in this window]
[in a new window]
  		FIG. 1. Electron microscopy of control (upper) and Gly972->Arg IRS-1 (lower) islets, showing a greater number of more immature granules in the latter.

 

View this table:
[in this window]
[in a new window]
  		TABLE 5 Volume density and number of immature and mature secretory granules in beta-cells from control and Gly972->Arg IRS-1 islets

 
Type 2 diabetes is a dual-disorder condition, characterized by insulin resistance and impaired insulin secretion. Although type 2 diabetes is likely to reflect a polygenic background to account for the defect of peripheral insulin action and reduced ß-cell response to glucose, recent studies have pointed out that a common defect may be shared by the ß-cell and the insulin-target cell. This hypothesis is supported by the observation that alteration of the insulin receptor or disruption of the insulin signaling pathway may result in both insulin resistance and reduced ß-cell function (3–5).

In the present study, we showed for the first time that human pancreatic islets from carriers of the Gly972->Arg amino acid polymorphism in IRS-1 have reduced insulin content, altered insulin release, and greater number of immature secretory granules. Because no major difference was seen in the percent of ß-cells in control and variant islets, it is suggested that these alterations are mainly attributable to functional abnormalities of the insulin-secreting cells. This might be caused by several factors, but the present experimental evidence supports the primary role of the Gly972->Arg amino acid polymorphism in IRS-1. In fact, the insulin signaling involving the IRS-1/phosphatidylinositol (PI) 3-kinase pathway has been shown to play an important role in insulin secretion by regulating the mobilization of intracellular Ca2+ stores (28). Moreover, in experimental rodent models, the IRS-1/PI 3-kinase system is altered in ß-cells carrying the Arg972 IRS-1 polymorphism (22,23).

The integrity of the insulin-signaling pathways is conceived as essential for normal insulin action and in particular for insulin-mediated glucose transport and metabolism. In our study, however, the Gly972->Arg amino acid polymorphism was not associated with any detectable defect in glucose utilization and/or oxidation. It should be recalled that the IRS-1/PI 3-kinase system is more involved in GLUT4 translocation in insulin-target tissues, whereas ß-cells express the GLUT2 transporter.

At variance with the impaired insulin response to glucose, islets expressing the Gly972->Arg amino acid polymorphism for IRS-1 exhibited a larger insulin release when challenged with arginine as compared to wild-type ß-cells. Arginine can stimulate insulin through various mechanisms, including depolarization of the ß-cell membrane because of its transport in a positively charged form (29), by production of nitric oxide (30), and, indirectly, by stimulation of glucagon secretion from {alpha}-cells (31). Although drawing conclusions in this regard is beyond the purpose of our study, it may be of interest that we did not find any evident change in the percent of {alpha}-cells between control and Arg972 IRS-1 islets. In any event, the effect of arginine on insulin secretion from Arg972 IRS-1 islets was accompanied by a relative hypersecretion of proinsulin, as suggested by the decreased insulin-to-proinsulin molar ratio, which is a feature of ß-cell dysfunction (32).

Human pancreatic ß-cells expressing the Gly972->Arg amino acid IRS-1 polymorphism showed a much larger number of immature secretory granules than control islets. In this regard, there is evidence that insulin stimulates pancreatic duodenal homeobox 1 (PDX-1) DNA-binding activity and insulin promoter activity via a pathway involving PI 3-kinase (33). More recently, it has been demonstrated that expression of PDX-1 in liver by recombinant adenovirus–mediated gene transfer results in the induction of expression of prohormone convertase 1/3 (PC 1/3), a protease that converts proinsulin to mature insulin (34). Although we have not directly addressed this issue, it seems possible that in the Arg972 IRS-1 ß-cells, the reduced insulin action might decrease PDX-1 activity, which, in turn, might reduce the expression of PC 1/3.

If the glucose and arginine challenges had divergent responses in terms of insulin release in Gly972->Arg islets, only a slight alteration of insulin secretion was detected in response to glibenclamide. This finding may well be in agreement with different and alternative pathways regulating insulin secretion, but it may also provide some clinical information. From these results it could be argued that sulfonylureas can be initially used for the treatment of type 2 diabetic patients carrying the Gly972->Arg IRS-1 polymorphism. Nonetheless, these individuals can be expected to fail soon, as suggested by the higher prevalence of the Gly972->Arg IRS-1 polymorphism in insulin-requiring type 2 diabetic patients as compared with patients who don’t require insulin (S.G., M.F., unpublished observations). By and large, these findings point out how, in the near future, it will be of importance to investigate the molecular characterization of the pathogenetic mechanisms responsible for hyperglycemia in order to identify the most appropriate therapeutic approach for a given patient.

Therefore, the presence of the Gly972->Arg IRS-1 polymorphism appears to be strongly associated with a primary defect of ß-cell function characterized by decreased glucose-stimulated insulin secretion, lower insulin content, and a reduced number of mature secretory granules. As such, this condition may represent a typical predisposing condition for future development of type 2 diabetes, since it seems unlikely that these ß-cells will be able to cope with any severe and/or long-lasting increased demand of insulin secretion as it occurs in the presence of a condition of insulin resistance.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
REFERENCES
 
The pancreata were procured through the local organ procurement agency, within the framework of a project aimed at clinical islet allotransplantation into diabetic patients and approved by the ethics committee of the University of Pisa. The presence of the polymorphism was detected by nested RT-PCR, as previously described (23). Procedures for islet preparation have also been reported in detail previously (24–27). Briefly, the enzyme collagenase (collagenase P; Roche Diagnostics) was used for digestion of the gland. The pancreatic duct was cannulated, and the digestion solution (collagenase, 1.5–2 mg/ml, dissolved in 200 ml Hanks’ balanced salt solution [HBSS]) was slowly injected to distend the tissue. After distension, the gland was placed into a 500-ml glass beaker, and the solution not used for distension was added into the beaker. This was loaded into a shaking water bath at 37°C, activated at 120 rpm. After ~10 min, the pancreas was shaken with forceps for 60 s; then the digestate was filtered through 300- and 90-µm mesh stainless steel filters, in sequence. The solution passed through the filter, and the tissue entrapped on the 300-µm mesh filter was placed back into the water bath for further digestion. The tissue remaining in the 90-µm filter was washed with HBSS and 2% human albumin. The same procedure of filtration, washing, and settling in HBSS solution was repeated at 8–10 intervals for up to 40–50 min. For purification, 3 ml of tissue was loaded into 220-ml plastic conicals and resuspended in 60 ml of 80% histopaque 1.077 (Sigma) in HBSS, topped with 40 ml of HBSS. After centrifugation at 800g for 5 min at 4°C, the islets were recovered at the interface between the two layers. The islets were then washed with HBSS and 2% human albumin, centrifuged at 800g for 2 min at 4°C, resuspended in M199 culture medium, and cultured at 37°C in a CO2 incubator for 5–6 days to perform the experiments described below.

Islet secretory function was evaluated as previously described (24–27). After a 30-min preincubation period at 37°C in Krebs-Ringer bicarbonate solution with 0.5% albumin (pH 7.4) containing 3.3 mmol/l glucose, the islets were incubated for 45 min in the Krebs-Ringer solution with 1.8, 5.5, or 16.7 mmol/l glucose or 3.3 mmol/l glucose plus 20 mmol/l arginine or 100 µmol/l glibenclamide. At the end of the incubation time, aliquots of the incubation medium were taken for insulin (Medgenix Diagnostics, Fleurs, Belgium; no cross-reactivity with human proinsulin) and proinsulin (Tecnogenetics, Turin, Italy; cross-reactivity with human insulin of <0.1%) immunoassay measurement. Islet insulin extraction was performed at the end of the incubation by overnight acid-alcohol incubation.

Glucose utilization and oxidation were determined at low (3.3 mmol/l) and high (16.7 mmol/l) glucose by measuring the formation of 3H2O from [5-3H]glucose and 14CO2 from [U- 14C]glucose, respectively, according to methods previously reported in detail (35).

Electron microscopy evaluation and quantification of ß- and {alpha}-cells, as well as insulin secretory granules, were performed according to standard procedures (36,37).

RNA extraction from human islets and semiquantitative RT-PCR analysis of insulin and insulin housekeeping control genes was performed as previously described (38).

Results are given as means ± SD. Comparison of data were performed by ANOVA or the two-tailed Student’s t test.


   ACKNOWLEDGMENTS
 
This work was supported in part by European Community Grant QLG1-CT-1999-00674 (G.S.) and COFIN 1999 and 2000 from the Italian Ministero dell’Università e Ricerca Scientifica e Tecnologica.


   FOOTNOTES
 
Address correspondence and reprint requests to Piero Marchetti, MD, Department of Endocrinology and Metabolism, Metabolic Unit, Ospedale Cisanello, via Paradisa 2, 56100 - Pisa, Italy. E-mail: marchant{at}immr.med.unipi.it.

Received for publication 26 June 2001 and accepted in revised form 14 January 2002.

HBSS, Hanks’ balanced salt solution; IRS-1, insulin receptor substrate 1; PC 1/3, prohormone convertase 1/3; PDX-1, pancreatic duodenal homeobox 1; PI, phosphatidylinositol.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 

  1. Mandroup-Poulsen T. Diabetes. BMJ316 :1221 –1225,1998[Free Full Text]
  2. Cavaghan MK, Ehrmann DA, Polonski KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest106 :329 –333,2000[Medline]
  3. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev19 :477 –490,1998[Abstract/Free Full Text]
  4. Ghosh S, Schork NJ: Genetic analysis of NIDDM. Diabetes45 :544 –551,1996[Abstract]
  5. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O: Amino acid polymorphism of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet342 :828 –832,1993[Medline]
  6. Giovannone B, Scaldaferri ML, Federici M, Porzio O, Lauro D, Fusco A, Sbraccia P, Borboni P, Lauro R, Sesti G: Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential. Diabetes Metab Res Rev16 :434 –441,2000[Medline]
  7. Hirayama I, Tamemoto H, Yokota H, Kubo SK, Wang J, Kuwano H, Nagamachi Y, Takeuchi T, Izumi T: Insulin receptor-related receptor is expressed in pancreatic beta cells and stimulates tyrosine phosphorylation of insulin receptor substrate-1 and -2. Diabetes48 :1237 –1244,1999[Abstract]
  8. Sigal RJ, Doria A, Warram JH, Krolewski AS: Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity and risk of non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab81 :1657 –1659,1996[Abstract]
  9. Imai Y, Fusco A, Suzuki Y, Lesniak MA, D’Alfonso R, Sesti G, Bertoli A, Lauro R, Accili D, Taylor SI: Variant sequences of insulin receptor substrate-1 in patients with non insulin dependent diabetes mellitus. J Clin Endocrinol Metab79 :1655 –1658,1994[Abstract]
  10. Laakso M, Malkki M, Kekalainen P, Kuusisto J, Deeb S: Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest94 :1141 –1146,1994[Medline]
  11. Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, Turner RC, UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and beta3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. Diabetologia39 :1505 –1511,1996[Medline]
  12. Mori H, Hashiramoto M, Kishimoto M, Kasuga M: Aminoacid polymorphism of the insulin receptor substrate-1 in Japanese non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab80 :2822 –2826,1995[Abstract]
  13. Ura S, Araki E, Kishikawa H, Shirotani T, Todaka M, Isami S, Shimoda S, Yoshimura R, Matsuda K, Motoyoshi S, Miyamura N, Kahn CR, Shichiri M: Molecular scanning of the IRS-1 gene in Japanese patients with non-insulin-dependent diabetes mellitus: identification of five novel mutations in IRS-1 gene. Diabetologia39 :600 –608,1996[Medline]
  14. Clausen JO, Hansen T, Bjorbaek C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Winther K, et al.: Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet346 :397 –402,1995[Medline]
  15. Hribal ML, Federici M, Porzio O, Lauro D, Borboni P, Accili D, Lauro R, Sesti G: The Gly->Arg72amino: acid polymorphism in IRS-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab85 :2004 –2013,2000[Abstract/Free Full Text]
  16. Koch M, Rett K, Volk A, Maerker E, Haist K, Deninger M, Renn W, Haring HU: Amino acid polymorphism Gly972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes. Exp Clin Endocrinol Diabetes107 :318 –322,1999[Medline]
  17. Armstrong M, Haldane F, Avery PJ, Mitcheson J, Stewart MW, Turnbull DM, Walker M: Relationship between insulin sensitivity and insulin receptor substrate-1 mutations in non-diabetic relatives of NIDDM families. Diabet Med13 :341 –345,1996[Medline]
  18. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF: Disruption of IRS-2 causes type 2 diabetes in mice. Nature391 :900 –903,1998[Medline]
  19. Stumvoll M, Fritsche A, Volke A, Stefan N, Madaus A, Maerker E, Teigeler A, Koch M, Machicao F, Haring H: The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucose-tolerant humans. Diabetes50 :882 –885,2001[Abstract/Free Full Text]
  20. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR: Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell96 :329 –339,1999[Medline]
  21. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan, D, Kahn CR: Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest104 :R69 –R75,1999[Medline]
  22. Porzio O, Federici M, Hribal ML, Lauro D, Accili D, Lauro R, Borboni P, Sesti G: The Gly 972 Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest104 :357 –364,1999[Medline]
  23. Federici M, Hribal ML, Ranalli M, Marselli L, Porzio O, Lauro D, Borboni P, Lauro R, Marchetti P, Melino G, Sesti G: The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J15 :22 –24,2001[Free Full Text]
  24. Marchetti P, Dotta F, Ling Z, Lupi R, Del Guerra S, Santangelo C, Realacci M, Marselli L, Di Mario U, Navalesi R: The function of pancreatic islets isolated from type 1 diabetic patient. Diabetes Care23 :701 –703,2000[Free Full Text]
  25. Rosati B, Marchetti P, Crociani O, Lecchi M, Lupi R, Arcangeli A, Olivotto M, Wanke E: Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K(+) channels in firing and release. FASEB J14 :2601 –2610,2000[Abstract/Free Full Text]
  26. Piro S, Lupi R, Dotta F, Patane G, Rabuazzo MA, Marselli L, Santangelo C, Realacci M, Del Guerra S, Purrello F, Marchetti P: Bovine islets are less susceptible than human islets to damage by human cytokines. Transplantation71 :21 –26,2001[Medline]
  27. Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, Carmellini M, Mosca F, Navalesi R, Marchetti P: The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol364 :205 –209,1999[Medline]
  28. Aspinwall CA, Lakey JRT, Kennedy RT: Insulin-stimulated insulin secretion in single pancreatic beta cells. J Biol Chem274 :6360 –6365,1999[Abstract/Free Full Text]
  29. Henquin JC: Regulation of insulin release by ionic and electrical events in beta-cells. Horm Res27 :168 –178,1987[Medline]
  30. Spinas GA: The dual role of nitric oxide in islet beta-cells. News Physiol Sci14 :49 –54,1999[Abstract/Free Full Text]
  31. Huypens P, Ling ZM, Pipeleers D, Schuit F: Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia43 :1012 –1019,2000[Medline]
  32. Zwalich WS, Kelley GG: The pathogenesis of NIDDM: the role of pancreatic beta-cell. Diabetologia38 :986 –991,1995[Medline]
  33. Wu H, MacFarlane WM, Tadayyon M, Arch JR, James RF, Docherty K: Insulin stimulates pancreatic-duodenal homeobox factor-1 (PDX1) DNA binding activity and insulin promoter activity in pancreatic beta cells. Biochem J344 :813 –818,1999
  34. Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seijffers R, Kopolovic J, Kaiser N, Karasik A: Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med6 :568 –572,2000[Medline]
  35. Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F: Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes49 :735 –740,2000[Abstract]
  36. Sabatini DD, Bench K, Barnatt RJ: Cytochemistry and electron microscopy: preservation of cellular ultrastructure and enzymatic activity by aldehyde fixation. J Cell Biol17 :19 –58,1963[Abstract/Free Full Text]
  37. Marselli L, Dotta F, Piro S, Santangelo C, Masini M, Lupi R, Realacci M, Del Guerra S, Mosca F, Boggi U, Purrello F, Navalesi R, Marchetti P: Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. J Clin Endocrinol Metab86 :4974 –4978,2001[Abstract/Free Full Text]
  38. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, Usellini L, Nano R, Bonini P, Bertuzzi F, Marlier LN, Davalli AM, Carandente O, Pontiroli AE, Melino G, Marchetti P, Lauro R, Sesti G, Folli F: High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes50 :1290 –1301,2000[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
K. Bouzakri, P. Ribaux, A. Tomas, G. Parnaud, K. Rickenbach, and P. A. Halban
Rab GTPase-Activating Protein AS160 Is a Major Downstream Effector of Protein Kinase B/Akt Signaling in Pancreatic {beta}-Cells
Diabetes, May 1, 2008; 57(5): 1195 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Muller, G. C. Huang, S. Amiel, P. M. Jones, and S. J. Persaud
Identification of Insulin Signaling Elements in Human {beta}-Cells: Autocrine Regulation of Insulin Gene Expression.
Diabetes, October 1, 2006; 55(10): 2835 - 2842.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Sesti, E. Laratta, M. Cardellini, F. Andreozzi, S. Del Guerra, C. Irace, A. Gnasso, M. Grupillo, R. Lauro, M. L. Hribal, et al.
The E23K Variant of KCNJ11 Encoding the Pancreatic {beta}-Cell Adenosine 5'-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2334 - 2339.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
R. Lupi, S. D. Guerra, M. Bugliani, U. Boggi, F. Mosca, S. Torri, S. D. Prato, and P. Marchetti
The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets
Eur. J. Endocrinol., February 1, 2006; 154(2): 355 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Masini, D. Campani, U. Boggi, M. Menicagli, N. Funel, M. Pollera, R. Lupi, S. Del Guerra, M. Bugliani, S. Torri, et al.
Hepatitis C Virus Infection and Human Pancreatic {beta}-Cell Dysfunction
Diabetes Care, April 1, 2005; 28(4): 940 - 941.
[Full Text] [PDF]

Home page
 DiabetesHome page
S. Del Guerra, R. Lupi, L. Marselli, M. Masini, M. Bugliani, S. Sbrana, S. Torri, M. Pollera, U. Boggi, F. Mosca, et al.
Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes
Diabetes, March 1, 2005; 54(3): 727 - 735.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. J. McGettrick, E. P. Feener, and C. R. Kahn
Human Insulin Receptor Substrate-1 (IRS-1) Polymorphism G972R Causes IRS-1 to Associate with the Insulin Receptor and Inhibit Receptor Autophosphorylation
J. Biol. Chem., February 25, 2005; 280(8): 6441 - 6446.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
M Schutt, J Zhou, M Meier, and H H Klein
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells
J. Endocrinol., December 1, 2004; 183(3): 445 - 454.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. C. Florez, M. Sjogren, N. Burtt, M. Orho-Melander, S. Schayer, M. Sun, P. Almgren, U. Lindblad, T. Tuomi, D. Gaudet, et al.
Association Testing in 9,000 People Fails to Confirm the Association of the Insulin Receptor Substrate-1 G972R Polymorphism With Type 2 Diabetes
Diabetes, December 1, 2004; 53(12): 3313 - 3318.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Marchetti, S. Del Guerra, L. Marselli, R. Lupi, M. Masini, M. Pollera, M. Bugliani, U. Boggi, F. Vistoli, F. Mosca, et al.
Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin
J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5535 - 5541.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Sesti, M. A. Marini, M. Cardellini, A. Sciacqua, S. Frontoni, F. Andreozzi, C. Irace, D. Lauro, A. Gnasso, M. Federici, et al.
The Arg972 Variant in Insulin Receptor Substrate-1 Is Associated With an Increased Risk of Secondary Failure to Sulfonylurea in Patients With Type 2 Diabetes
Diabetes Care, June 1, 2004; 27(6): 1394 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. Otani, R. N. Kulkarni, A. C. Baldwin, J. Krutzfeldt, K. Ueki, M. Stoffel, C. R. Kahn, and K. S. Polonsky
Reduced {beta}-cell mass and altered glucose sensing impair insulin-secretory function in {beta}IRKO mice
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E41 - E49.
[Abstract] [Full Text]

Home page
 DiabetesHome page
S. Srivastava and H. J. Goren
Insulin Constitutively Secreted by {beta}-Cells Is Necessary for Glucose-Stimulated Insulin Secretion
Diabetes, August 1, 2003; 52(8): 2049 - 2056.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. Sesti, M. Cardellini, M. A. Marini, S. Frontoni, M. D'Adamo, S. Del Guerra, D. Lauro, P. De Nicolais, P. Sbraccia, S. Del Prato, et al.
A Common Polymorphism in the Promoter of UCP2 Contributes to the Variation in Insulin Secretion in Glucose-Tolerant Subjects
Diabetes, May 1, 2003; 52(5): 1280 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
O. Tschritter, A. Fritsche, F. Shirkavand, F. Machicao, H. Haring, and M. Stumvoll
Assessing the Shape of the Glucose Curve During an Oral Glucose Tolerance Test
Diabetes Care, April 1, 2003; 26(4): 1026 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Federici, A. Petrone, O. Porzio, C. Bizzarri, D. Lauro, R. D'Alfonso, I. Patera, M. Cappa, L. Nistico, M. Baroni, et al.
The Gly972->Arg IRS-1 Variant Is Associated With Type 1 Diabetes in Continental Italy
Diabetes, March 1, 2003; 52(3): 887 - 890.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marchetti, P.
Right arrow Articles by Del Prato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marchetti, P.
Right arrow Articles by Del Prato, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum